Evolent Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated October 1, 2018, details the closing of a material definitive agreement and the completion of an asset acquisition by Evolent Health, Inc. (EVH, Inc.). The filing reports on the merger of NCIS Holdings, Inc. (the "Company") into a wholly-owned subsidiary of EVH LLC, effective October 1, 2018.
Key Financial Metrics and Transaction Details
The filing does not provide standard operating financial metrics such as revenue, profit, cash flow, or margins for the reporting period. Instead, it discloses specific transaction consideration values:
- Cash Consideration: Approximately $115.7 million paid from cash on hand.
- Equity Consideration: Approximately 3,075,929 Class B Shares and Class B Units issued to Equityholders.
- Contingent Consideration: Up to $20,000,000 in additional consideration, subject to the Company's 2019 operating results.
- Payment Structure for Contingent Consideration: 50% cash and 50% Class B Shares/Units for Equityholders (or 100% cash at EVH's election); cash or Class A Shares for certain management members.
Material Changes and Agreements
The primary material change is the acquisition of NCIS Holdings, Inc. Key structural elements include:
- Merger Completion: Merger Sub merged with and into NCIS Holdings, Inc., which survived as a wholly-owned subsidiary of EVH LLC.
- Exchange Agreements: EVH entered into Exchange Agreements allowing certain Equityholders to exchange Class B Shares and Units (or shares of "Blocker" subsidiaries) for Class A Shares. The initial exchange rate is one Class B Share plus one Class B Unit for one Class A Share.
- Unregistered Sales: The issuance of Class B Shares and Units was exempt from registration under Section 4(a)(2) of the Securities Act, sold only to accredited investors.
Outlook, Risks, and Management Commentary
Management has issued forward-looking statements regarding the acquisition, noting that actual results may differ materially due to various risks:
- Integration Risks: Difficulties in integrating the acquired company, diversion of management resources, and unanticipated costs.
- Performance Risks: Future revenues may be less than expected, and the timing/extent of new lives coming onto the platform may not meet expectations.
- Dilution: The transaction may dilute existing stockholders.
- Disclaimer: EVH disclaims any obligation to update forward-looking statements to reflect future events.
Investor Verification Checklist
- Verify the specific terms of the $20 million contingent consideration and the 2019 operating result thresholds required for payout.
- Review the full text of the Merger Agreement (Exhibit 2.1) and Exchange Agreements (Exhibits 10.1 and 10.2) for detailed representations and warranties.
- Confirm the impact of the 3,075,929 new Class B Shares/Units on existing shareholder dilution.
- Assess the integration plan and potential costs associated with merging NCIS Holdings, Inc. into the Evolent platform.
- Check subsequent filings for updates on the 2019 performance metrics tied to the earn-out.